Tokyo, Dec. 19 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060118) titled 'A database study on the expression of immune-related adverse events in immune checkpoint inhibitors in combination with chemotherapy for non-squamous cell carcinoma' on Dec. 18.
Study Type:
Observational
Primary Sponsor:
Institute - Chugai Pharmaceutical Co., Ltd.
Condition:
Condition - Non-squamous cell carcinoma
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - Confirmation of safety in patients who received immune checkpoint inhibitors in combination with chemotherapy in non-squamous cell carcinoma
Basic objectives2 - Others
Eligibility:
Age-lower limit - No...